Seoeun Lee
Senior Director, External Innovation Eli Lilly & Co.
Seoeun Lee has been a member of Eli Lilly’s Neuroscience Search & Evaluation team since January 2025, focusing on Psychiatry and Sleep disease areas. Most recently, she served as the S&E lead on Lilly’s acquisition of Centessa Pharmaceuticals and AtaiBeckley. Prior to this role, Seoeun worked at Boston Consulting Group, where she partnered with biopharma and biotech companies on building growth strategies. Seoeun holds a PhD in Biomedical Sciences from Columbia University, where her doctoral research focused on the basic science of neurodevelopment, and a B.S. in Biological Sciences from the Korea Advanced Institute of Science and Technology.
Seminars
Thursday 10th December 2026
Panel Discussion | Pharma’s Appetite for Innovation: What do Global Partners Seek in Novel Targets and Modalities?
9:30 am
- Which CNS indications and targets hold the greatest promise for investable disease‑modifying therapies?
- What stage and type of data are needed to confidently support safety, target engagement, and MoA of new targets under evaluation?
- Do you prioritize new modalities aligned with in‑house expertise, or are you open to partnering with specialists in novel modalities?
